Exploratory circulating tumour DNA (ctDNA) methylation profiling (PredicineEPIC) assessed molecular response dynamics and ERBB2 copy number variation.<h4>Results</h4>From 18 September 2022 to 12 December 2024, 32 patients were enrolled; 24 proceeded to D2 resection. Here, ERBB2 is linked to neoplasm.